Literature DB >> 16009865

Accuracy of a pharmacovigilance algorithm in diagnosing drug hypersensitivity reactions.

Said Benahmed1, Marie-Christine Picot, Francine Dumas, Pascal Demoly.   

Abstract

BACKGROUND: This study was performed to evaluate the diagnostic accuracy of a pharmacovigilance algorithm in patients with 1 or more histories suggestive of drug hypersensitivity.
METHODS: We performed a retrospective analysis of a clinic case series. We analyzed patients with suspected clinical reactions of drug hypersensitivity. Patients with severe skin reactions were excluded. Patients with history of drug allergy were subjected to additional testing to validate this history. Following a detailed clinical history, skin tests were performed. If skin tests were not available or validated, drug provocation tests were conducted. Assessment of causality was established by an investigator unaware of drug testing results using a pharmacovigilance algorithm that was then compared with the final diagnosis.
RESULTS: A total of 677 consecutive patients with 1001 reactions were analyzed. No score could be given because of the absence of 1 of the criteria required for 204 reactions (20.4%). For 720 reactions (71.9%), a dubious causality assessment score was given. Drug hypersensitivity was confirmed by drug testing in 175 reactions (17.5%) and eliminated in 826 reactions (82.5%). Sensitivity of the algorithm was 10.3% and specificity was 76.9%. Although there were 1.7% false-positive scores, there were no false-negative scores. The logistic regression that was performed to look for independent clinical risk factors linked to the drug hypersensitivity diagnosis found 3 parameters: likely causality assessment score, drug reintroduction in clinical history, and delay between reaction and last drug intake of less than 1 hour.
CONCLUSION: A pharmacovigilance algorithm is not accurate for the diagnosis of drug hypersensitivity reactions and cannot replace drug allergy testing.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16009865     DOI: 10.1001/archinte.165.13.1500

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  9 in total

1.  Modelling the time to onset of adverse reactions with parametric survival distributions: a potential approach to signal detection and evaluation.

Authors:  François Maignen; Manfred Hauben; Panos Tsintis
Journal:  Drug Saf       Date:  2010-05-01       Impact factor: 5.606

2.  Drug-induced anaphylaxis: a decade review of reporting to the Portuguese Pharmacovigilance Authority.

Authors:  Inês Ribeiro-Vaz; Joana Marques; Pascal Demoly; Jorge Polónia; Eva Rebelo Gomes
Journal:  Eur J Clin Pharmacol       Date:  2012-08-23       Impact factor: 2.953

3.  Safety aspects of iodinated contrast media related to their physicochemical properties: a pharmacoepidemiology study in two Tuscany hospitals.

Authors:  Francesco Lapi; Enrica Cecchi; Claudio Pedone; Francesco Attanasio; Grazia Banchelli; Alfredo Vannacci; Marina Di Pirro; Martina Moschini; Valentina Berni; Rosanna Matucci; Elisabetta Cini; Antonino Scalia; Enrico Tendi; Alessandro Mugelli
Journal:  Eur J Clin Pharmacol       Date:  2008-04-10       Impact factor: 2.953

Review 4.  The Value of In Vitro Tests to DiminishDrug Challenges.

Authors:  Cristobalina Mayorga; Inmaculada Doña; Ezequiel Perez-Inestrosa; Tahia D Fernández; Maria J Torres
Journal:  Int J Mol Sci       Date:  2017-06-07       Impact factor: 5.923

Review 5.  Clinical value of in vitro tests for the management of severe drug hypersensitivity reactions.

Authors:  Yuttana Srinoulprasert; Ticha Rerkpattanapipat; Mongkhon Sompornrattanaphan; Chamard Wongsa; Duangjit Kanistanon
Journal:  Asia Pac Allergy       Date:  2020-10-29

6.  [The COVID-19 RNA vaccine - what allergic risk?]

Authors:  P Demoly
Journal:  Bull Acad Natl Med       Date:  2021-02-09       Impact factor: 0.144

7.  The role of in vitro testing in pharmacovigilance for ß-lactam-induced serum sickness-like reaction: A pilot study.

Authors:  Abdelbaset A Elzagallaai; Awatif M Abuzgaia; Blanca R Del Pozzo-Magaña; Eman Loubani; Michael J Rieder
Journal:  Front Pharmacol       Date:  2022-08-30       Impact factor: 5.988

Review 8.  An EAACI task force report: recognising the potential of the primary care physician in the diagnosis and management of drug hypersensitivity.

Authors:  I Doña; J C Caubet; K Brockow; M Doyle; E Moreno; I Terreehorst; M J Torres
Journal:  Clin Transl Allergy       Date:  2018-05-10       Impact factor: 5.871

Review 9.  [Update on perioperative hypersensitivity reactions: joint document of the Brazilian Society of Anesthesiology (SBA) and Brazilian Association of Allergy and Immunology (ASBAI) - Part I: post-crisis guidelines and treatment].

Authors:  Maria Anita Costa Spindola; Dirceu Solé; Marcelo Vivolo Aun; Liana Maria Tôrres de Araújo Azi; Luiz Antonio Guerra Bernd; Daniela Bianchi Garcia; Albertina Varandas Capelo; Débora de Oliveira Cumino; Alex Eustáquio Lacerda; Luciana Cavalcanti Lima; Edelton Flávio Morato; Rogean Rodrigues Nunes; Norma de Paula Motta Rubini; Jane da Silva; Maria Ângela Tardelli; Alexandra Sayuri Watanabe; Erick Freitas Curi; Flávio Sano
Journal:  Braz J Anesthesiol       Date:  2020-09-17
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.